BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Odyssey Thera, Inc. Awarded 19th Patent for Drug Discovery and Re-Purposing Technologies


5/4/2011 11:12:27 AM

SAN RAMON, Calif., May 4, 2011 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,935,493, entitled "Protein fragment complementation assays for high-throughput and high-content screening."

Claims granted in the patent broadly cover the application of contextual high-content assays to diverse biological events, and the use of these methods for novel drug discovery and drug re-indication. The concept of utilizing drugs with well-established pharmacology and safety characteristics for a novel therapeutic focus drug re-indication or "re-repurposing" has been proposed as a solution for improving success rates of therapeutic development(1).

"This patent, in concert with our existing IP, provides unprecedented coverage of cellular signaling space," said John K. Westwick, Ph.D., Odyssey Thera President and CEO. "Access to all target classes and pathways is essential for deciphering compound and target mechanisms. Technologies protected by this patent, combined with our proprietary strategies for expediting preclinical development, represent a unique platform for fast-tracking new therapeutic development."

About Odyssey Thera

Odyssey Thera, Inc. is a privately held technology company committed to developing breakthroughs in cellular and biochemical analysis. Novel technologies developed at Odyssey are improving the success rate of new therapeutic development, and providing new solutions for environmental monitoring, diagnostic, bioprocess and agricultural applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.

(1) Huang, R. et al., (2011) Science Translational Medicine; Apr 27;3(80):80ps16.

SOURCE Odyssey Thera, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES